Skip to main content
. Author manuscript; available in PMC: 2023 Apr 15.
Published in final edited form as: Clin Cancer Res. 2023 Jan 18;29(8):1429–1439. doi: 10.1158/1078-0432.CCR-22-2263

Table 3. Summary Pharmacokinetic Parameters on D-7 by Dose Level of AZD3965.

Dose Level (mg) Number of Patients Cmax (ng/mL) AUC0-24 (ng/mL•h) Half-Life (h) Cl/F (L/h) Vz/F (L)
5 3 21.7–65.6 212±85 51.9±4.9 14.9±3.7 1115±290
10 5 28.2–182.2 731±311 45.4±6.4 9.5±1.9 630±174
20 13 117.6–431.2 1521±497 36.5±5.7 11.4±3.8 595±206
30 11 191.2–808.0 3466±1952 38.1±10.4 9.5±5.2 534±363

Dose level of 20 mg includes data from AZD3965 20 mg OD and 10 mg BD dose cohorts (both received 20 mg on D-7) and dose level of 30 mg includes data from AZD3965 30 mg OD and 15 mg BD dose cohorts (both received 30 mg on D-7). All values expressed as mean ± standard deviation, except for Cmax, where range is presented.

Abbreviations: AUC0-24, area under the curve during 24 hours; Cmax, maximum observed plasma concentration; Cl/F, apparent clearance of distribution; D=day; Vz/F, apparent volume of distribution.